Tempus AI rises on rare cancer research collaboration
BUZZ-Tempus AI rises on rare cancer research collaboration ** Shares of AI-enabled precision medicine firm Tempus AI TEM.O rise 3.7% to $53.85
** Co announces research collaboration with Angiosarcoma Awareness, a patient-driven charity focused on supporting patients and funding research for angiosarcoma
** Angiosarcoma is a rare and aggressive cancer that starts in cells lining blood vessels; about 1,000 people are diagnosed in the U.S. each year, co says
** Co says collaboration will use about 600 de-identified angiosarcoma records with DNA and RNA sequencing data, along with clinical information where available
** Says the dataset is one of the largest known molecular datasets for angiosarcoma and could help find disease patterns and potential treatment opportunities
** Including session's move, TEM down 7.6% YTD
(Reporting by Kunal Das in Bengaluru)
Recent news on Tempus AI
See all newsU.S. STOCKS ON THE MOVE-Tempus AI, Choice Hotels, Palantir
Tempus AI rises after surprise quarterly profit
Tempus AI Q3 revenue slightly beats estimates; raises guidance
Brief: Tempus Receives Ivdr Certification For Xr Rna Sequencing For Solid Tumor Profiling
Brief: Tempus Expands Strategic Collaboration With Bristol Myers Squibb